Eli Lilly’s Mounjaro, an injectable drug used for Type 2 diabetes and chronic weight management, has emerged as India’s top-selling medicine brand, with sales of Rs 1,544 crore in the 12 months ending October 2026. This represents a 229.4 per cent increase over the preceding 12-month period, when its sales stood at approximately Rs 469 crore, according to the latest data from Pharmarack.

The surge comes even as cheaper alternatives to weight-loss drugs have entered the Indian market. Lower-cost versions of semaglutide, a medicine also used to treat diabetes and manage weight, became available after Novo Nordisk’s patent expired in March this year. Several Indian pharmaceutical companies have since launched their own versions, making the treatment more affordable.…